Destiny Pharma plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Destiny Pharma plc
The company said it would discontinue the Phase III trial of the MRSA drug for futility, leaving it with no major catalysts and an uncertain cash position.
A new research program exploring an additional indication for XF-73 will help the UK biotech's licensing discussions for the nasal gel.
What on earth would make a biotech company change the primary endpoint half way through a Phase III program and not discuss it with the FDA? There are at least two scenarios, neither of them good.
Destiny Pharma's XF-73 achieved an "exceptionally high" 99.5% reduction in Staphylococcus aureus bacterial nasal carriage in a mid-stage trial, a result that should attract a number of potential partners for the UK firm.